GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases.
GSK is sourcing early-stage science across a wide range of technologies and disease areas, while placing more selective bets ...
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
The approval represents a win in what’s been a difficult regulatory environment of late for vaccine makers, and could boost uptake of a shot that’s posted flattening sales after an initially strong ...
GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to accelerate drug development and halt the nation’s slide down global life science ...
Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed complete responses in preclinical combination studies of Pol Theta Helicase DC with ...
SAN MATEO, Calif., Jan. 7, 2026 /PRNewswire/ -- Helix, the leading enterprise genomics company, today announced a multi-year strategic collaboration with GSK, the global biopharma company. This ...
GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program. The recombinant protein vaccine, dubbed GSK3943104, did not meet the study’s primary efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results